share_log

Smart for Life CEO Issues Year-End Letter to Shareholders

Smart for Life CEO Issues Year-End Letter to Shareholders

智慧生命行政總裁向股東發出年終信
GlobeNewswire ·  2023/01/12 09:06

2022 Marked Transformative Year for Smart for Life; Built a Solid Foundation Through Acquisitions and Anticipates Significant Growth in 2023

2022年標誌着Smart for Life的變革之年;通過收購奠定了堅實的基礎,並預計2023年將實現顯著增長

MIAMI, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) ("Smart for Life" or the "Company"), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today provided the following letter to shareholders from the Company's CEO, Darren Minton:

邁阿密,2023年1月12日(環球通訊社)--智能生活公司(納斯達克代碼:SMFL)(“生活智能”或“公司”)作為全球健康與健康行業營銷和營養食品及補充劑製造領域的高增長全球領導者,今天,該公司首席執行官達倫·明頓向股東提供了以下信件:

"2022 was truly a transformative year for Smart for life and as we look toward a promising year ahead, I am proud to reflect on all that we have achieved. In the beginning of 2022, we completed our Initial Public Offering and raised gross proceeds of $14.4 million. We have now completed five major acquisitions since our formation which not only validates our ability to acquire accretive businesses at attractive multiples but also our ability to successfully integrate these companies within our organization. Although 2022 has certainly been a tumultuous year in the capital markets, our proactive "Buy and Build" strategy is working—we are currently generating pro forma revenues in excess of $30 million and anticipate expanding to over $100 million in annualized revenues in the next twelve months based on anticipated acquisitions and organic growth. In addition, as we have publicly announced, we have an objective of achieving $300 million in revenues within the next 36 months.

2022年對Smart來説確實是變革性的一年,當我們展望未來充滿希望的一年時,我很自豪地反思我們所取得的所有成就。2022年初,我們完成了首次公開募股,籌集了1440萬美元的毛收入。自我們成立以來,我們已經完成了五項重大收購,這不僅驗證了我們以誘人的倍數收購增值業務的能力,也驗證了我們成功將這些公司整合到我們組織內的能力。儘管2022年肯定是資本市場動盪的一年,但我們積極的“購買並構建”戰略正在奏效-我們目前的預計收入超過3000萬美元,並預計在未來12個月內基於預期的收購和有機增長,年化收入將擴大到1億美元以上。此外,正如我們已經公開宣佈的那樣,我們的目標是在未來36個月內實現3億美元的收入。

Through our subsidiaries, we boast a dynamic, exciting mix of brands and capabilities including Ceautamed Worldwide LLC, GSP Nutrition Inc. (which owns a license in the U.S. and Canada for the exclusive use of certain of the Sports Illustrated brands in the fields of dietary and nutritional supplements), Doctors Scientific Organica, LLC, Bonne Santé Natural Manufacturing, Inc. and Nexus Offers, Inc. Our current businesses include two state-of-the-art FDA-certified contract manufacturing facilities, spanning an aggregate of 60,000 sq. ft., along with consumer brands, digital marketing services, and licensing agreements. We offer a variety of cutting-edge formulary and manufacturing capabilities including capsules, tablets, powders, health bars, baked goods, functional foods, and other product types and delivery methods.

通過我們的子公司,我們擁有充滿活力、令人興奮的品牌和能力組合,包括Ceautame Worldwide LLC、GSP Nutrition Inc.(它在美國和加拿大擁有在飲食和營養補充劑領域獨家使用某些體育畫報品牌的許可證)、Doctors Science Organica,LLC、Bonne SantéNatural製造公司和Nexus Offers,Inc.。我們目前的業務包括兩個最先進的FDA認證的合同製造設施,總面積達60,000平方米。以及消費品牌、數字營銷服務和許可協議。我們提供各種尖端配方和製造能力,包括膠囊、片劑、粉末、健康棒、烘焙食品、功能食品和其他產品類型和交付方式。

We achieved several noteworthy milestones in 2022:

我們在2022年取得了幾個值得注意的里程碑:

  • Launched new line of Greens First protein bars
  • Achieved strong revenue growth: Q3 2022 revenues increased 59.1% year-over-year to $5.4 million due to successful acquisition strategy; Q3 2022 profit margin increased to 49.1%, versus 42.6% for the same period last year
  • Initiated capital restructuring designed to increase shareholders' equity and contribute toward our continued Nasdaq listing requirements
  • Opened new corporate headquarters, consolidated operations aimed at delivering greater savings and efficiencies at scale
  • Executed Letter of Intent for strategic co-venture with Cosmos Health, Inc. (Nasdaq: COSM) to cross market products and services in their reciprocal markets
  • Announced Letter of Intent to acquire a premier eCommerce nutraceuticals company with operations in North America; acquisition is expected to add over $12 million of revenue and to be accretive to earnings
  • Formed Smart Acquisition Group, LLC to accelerate M&A activities; named Stuart Benson, JD as Managing Director
  • Completed strategic acquisition of Ceautamed Worldwide LLC owner of Greens First Brand; expected to be highly synergistic and accretive, while adding established medical distribution channels and expanding product portfolio
  • Partnered with Milk Dust for manufacturing of its proprietary products designed to support mother's breast milk production during baby formula shortage
  • Aided shipment of over 100,000 meal replacement bars to Ukraine to help those in need
  • Selected by Amazon to launch various Smart for Life products in Singapore
  • Acquired Sports Illustrated™ trademark rights as described above
  • 推出新的綠色第一蛋白質棒系列
  • 實現了強勁的收入增長:由於成功的收購戰略,2022年第三季度的收入同比增長59.1%,達到540萬美元;2022年第三季度的利潤率從去年同期的42.6%提高到49.1%
  • 啟動資本重組,旨在增加股東權益,併為我們繼續滿足納斯達克上市要求做出貢獻
  • 開設新的公司總部,整合運營,旨在實現更大規模的節約和效率
  • 與Cosmos Health,Inc.(納斯達克代碼:COSM)簽署戰略合資意向書,在各自的互惠市場交叉銷售產品和服務
  • 宣佈收購一家在北美開展業務的頂級電子商務營養食品公司的意向書;收購預計將增加1200多萬美元的收入,並增加收益
  • 成立了智能收購集團LLC以加快併購活動;任命斯圖爾特·本森JD為董事的管理
  • 完成對Ceautame Worldwide LLC的戰略收購,擁有Greens First Brand;預計將實現高度協同和增值,同時增加現有的醫療分銷渠道並擴大產品組合
  • 與奶粉公司合作生產其專有產品,旨在支持嬰兒配方奶粉短缺期間母親的母乳生產
  • 協助向烏克蘭運送超過10萬條代餐棒材,以幫助有需要的人
  • 被亞馬遜選中在新加坡推出各種智能生活產品
  • 如上所述獲得《體育畫報》™商標權

In summary, Smart for Life represents an exciting opportunity to invest in a dynamic, innovative, proactive organization capitalizing on the fragmented yet rapidly growing nutraceutical market. We believe our proactive acquisition strategy, targeting accretive cash flow positive companies, combined with strategies to enhance organic growth, represents the best path to drive long-term value for shareholders. We are extremely well positioned to take advantage of the opportunities in front of us and are excited about the outlook for 2023 and beyond."

總而言之,Smart for Life代表着一個令人興奮的機會,可以投資於一個充滿活力、創新、積極主動的組織,利用支離破碎但快速增長的營養食品市場。我們相信,我們的主動收購戰略,目標是增加現金流的積極公司,與促進有機增長的戰略相結合,是為股東推動長期價值的最佳途徑。我們處於非常有利的地位,可以利用擺在我們面前的機會,並對2023年及以後的前景感到興奮。

About Smart for Life, Inc.

關於Smart for Life,Inc.

Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-six months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: .

Smart for Life,Inc.(納斯達克代碼:SMFL)從事各種營養及相關產品的開發、營銷、製造、收購、運營和銷售,重點是健康和健康。作為一家公開持股的全球控股公司,該公司正在執行一項先買後建戰略,通過一系列增值收購創建一家垂直整合的公司,目標是在未來36個月內將收入至少為3億美元的公司聚集在一起。為了推動增長和收益,Smart for Life正在開發專有產品,並收購其他盈利公司,包括品牌、製造和分銷渠道。該公司目前經營着五家子公司,包括Doctors Science Organica、Nexus Offers、Bonne SantéNatural Manufacturing、GSP Nutrition和Ceautame Worldwide。有關Smart for Life的更多信息,請訪問:。

Video regarding the Company's manufacturing facility at Bonne Santé Natural Manufacturing is available at: .

有關該公司在Bonne SantéNatural Manufacturing的製造設施的視頻可在以下網址獲得:

Investor material and a Fact Sheet with additional information about Smart for Life is available at: .

投資者材料和包含有關Smart for Life的更多信息的情況説明書可在以下網站獲得:

Forward-Looking Statements

前瞻性陳述

This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management's beliefs, assumptions and expectations of Smart for Life's future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in "Risk Factors" included in our filings with the Securities and Exchange Commission.

本新聞稿可能包含有關我們對未來預期、計劃和前景的看法的信息,這些信息構成了前瞻性陳述。所有前瞻性陳述都是基於管理層對Smart for Life未來經濟表現的信念、假設和預期,並考慮到目前掌握的信息。這些陳述不是對歷史事實的陳述。儘管Smart for Life相信這些前瞻性陳述中反映的預期是基於合理的假設,但它不能保證其預期將會實現。除非法律要求,否則Smart for Life不承擔更新本文中包含的任何陳述(包括任何前瞻性陳述)的任何責任。不能保證Smart for Life將成功收購其收購目標。前瞻性陳述受許多因素、風險和不確定因素的影響,其中一些因素目前尚不為我們所知,這些因素可能會導致Smart for Life的實際結果、業績或財務狀況與對未來結果、業績或財務狀況的預期大不相同。實際結果可能與前瞻性陳述中討論的預期大不相同。可能導致實際結果與預期大相徑庭的因素包括一般行業考慮因素、監管變化、地方或國家經濟狀況的變化以及在我們提交給證券交易委員會的文件中包含的“風險因素”中列出的其他風險。

Disclaimer

免責

The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

本新聞稿中提供的信息僅供一般知識使用,並不能替代特定醫療條件下的專業醫療建議或治療。如果您有任何關於健康狀況的問題,請務必諮詢您的醫生或其他有資質的醫療保健提供者。本信息不用於診斷、治療、治癒或預防任何疾病。

Investor Relations Contact

投資者關係聯繫人

Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Cresendo Communications,LLC
電話:(212)671-1021
郵箱:smfl@cresendo-ir.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論